LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Organon & Co

Fermé

SecteurSoins de santé

10.34 -0.19

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.2

Max

10.55

Chiffres clés

By Trading Economics

Revenu

-174M

-87M

Ventes

81M

1.6B

P/E

Moyenne du Secteur

3.866

35.293

BPA

1

Rendement du dividende

8.08

Marge bénéficiaire

-5.443

Employés

10,000

EBITDA

124M

449M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+73.08% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

8.08%

3.07%

Prochains Résultats

30 oct. 2025

Date du Prochain Dividende

11 déc. 2025

Date du Prochain Détachement de Dividende

11 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

190M

2.7B

Ouverture précédente

10.53

Clôture précédente

10.34

Sentiment de l'Actualité

By Acuity

50%

50%

185 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Organon & Co Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

16 sept. 2025, 17:03 UTC

Principaux Mouvements du Marché

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept. 2025, 16:49 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

GD Culture Shares Drop After Deal for Pallas Capital

16 sept. 2025, 16:11 UTC

Principaux Mouvements du Marché

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept. 2025, 21:10 UTC

Acquisitions, Fusions, Rachats

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 sept. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

16 sept. 2025, 20:25 UTC

Résultats

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept. 2025, 20:24 UTC

Résultats

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept. 2025, 18:40 UTC

Acquisitions, Fusions, Rachats

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept. 2025, 16:53 UTC

Résultats

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

16 sept. 2025, 16:15 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Commodities Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Energy Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Acquisitions, Fusions, Rachats

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparaison

Variation de prix

Organon & Co prévision

Objectif de Prix

By TipRanks

73.08% hausse

Prévisions sur 12 Mois

Moyen 18 USD  73.08%

Haut 18 USD

Bas 18 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

8.53 / 9.18Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

185 / 371Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat